102. Great Promise but Still More Questions in the Genomic Era: Examples from the Nontuberculous Mycobacteria
Session: Symposium: Genomic Tools for Personalized Infectious Diseases Management and Outbreak Investigations
Thursday, October 3, 2013: 10:30 AM
Room: The Moscone Center: 135 (Hall E)
  • MaryAnne DeGroote - Supplemental Slides.pdf (127.5 kB)
  • Mary Ann Degroote, MD, Colorado State University, College of Veterinary Medicine and Biomedical Sciences, Fort Collins, CO

    Dr. De Groote is an Infectious Disease clinician who works at Colorado State University (CSU) in the Mycobacterial Research Laboratories. She is currently working on two areas related to the study of mycobacteria. One, with Dr. John Belisle, is the development of novel tuberculosis prognostic and diagnostic assays. The second area involves novel therapies for nontuberuclous (NTM) mycobacterial infections such as Mycobacterium abscessus andMycobacterium avium complex. She works closely with Dr. Scott Franzblau and colleagues on projects funded by the American Lung Association and NTMir and Cystic Fibrosis grants to find new drugs against Mycobacterium abscessus and other NTM. In addition to screening compound libraries for anti-NTM activity the group has begun to characterize the efficacy of the most promising agents in animal models. Testing of novel compounds is done under a grant awarded to Dr. Anne Lenaerts under an NIAID contract for preclinical services for the NTM. In addition to this research, she has also strived to bring the basic scientists together with clinical and clinical trialist colleagues to strengthen research up and down the Colorado Front Range. Partners include Denver Health, National Jewish Health, UC Denver, industrial partners and CSU). The hope is to bring real discoveries closer to patients.

    Previous Presentation | Next Presentation >>

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.